Syngoi Technologies and Ribbon Bio commence strategic collaboration to advance Gene Therapies with Synthetic DNA Collaboration builds upon Syngoi’s synthetic DNA manufacturing capabilities and Ribbon’s algorithm-driven technology to produce pristine…
Read More
Check new clips.
1º SYNODNA oDNA: NOVEDOSO ADN LINEAL CERRADO SINTÉTICO PARA NUEVAS TERAPIAS AVANZADAS Número de expediente: ZL-2024/00341 Actuación cofinanciada por el Gobierno Vasco y la Unión Europea a través del Fondo…
Read More
Syngoi welcomes Buenavista Equity Partners after the launch of BV Healthcare Growth Innvierte I fund
Syngoi welcomes Buenavista Equity Partners after the launch of BV Healthcare Growth Innvierte I fund At Syngoi, we are pleased to announce the addition of Buenavista Equity Partners to…
Read More
CEPI partners with Afrigen to accelerate development and access to mRNA vaccine CEPI and Afrigen Biologics have teamed up on an innovative project to accelerate the development of mRNA…
Read More
Syngoi Technologies Expands DNA Manufacturing Capacity After Series B Investment. Syngoi's funding round enables production of DNA at kilograms scale and accommodates over 15 concurrent projects. Asahi Kasei Medical,…
Read More
Syngoi Technologies Wins the ON Bizkaia Award for Business Innovation! April 23, 2024. Bizkaia. We are thrilled to announce that Syngoi Technologies has been honored with the prestigious ON Bizkaia…
Read More
